The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon-Reference-Cited by-同舟云学术

The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon

Published:2020-10 Issue: Volume:197 Page:106166
ISSN:0303-8467
Container-title:Clinical Neurology and Neurosurgery
language:en
Short-container-title:Clinical Neurology and Neurosurgery

Author:

Capone Fioravante^ORCID,De Vincentis Antonio,Ferraro Elisabetta,Rossi Mariagrazia,Motolese Francesco^ORCID,Picardi Antonio,Giannetti Barbara,Di Battista Giancarlo,Vespasiani-Gentilucci Umberto,Di Lazzaro Vincenzo^ORCID

Funder

Merck Serono Spa Italy

Publisher

Elsevier BV

Subject

Clinical Neurology,General Medicine,Surgery

Reference22 articles.

1. Multiple sclerosis: side effects of interferon beta therapy and their management;Walther;Neurology,1999

2. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes;Tremlett;Mult. Scler.,2004

3. Acute liver failure in a patient with multiple sclerosis treated with interferon-beta;Montero;Mult. Scler.,2007

4. Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study;Sabidó-Espin;BMC Neurol.,2017

5. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance;Francis;Drug Saf.,2003

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of candidate biomarkers and pathways associated with multiple sclerosis using bioinformatics and next generation sequencing data analysis;2023-12-07